JP2022511209A5 - - Google Patents

Info

Publication number
JP2022511209A5
JP2022511209A5 JP2020572856A JP2020572856A JP2022511209A5 JP 2022511209 A5 JP2022511209 A5 JP 2022511209A5 JP 2020572856 A JP2020572856 A JP 2020572856A JP 2020572856 A JP2020572856 A JP 2020572856A JP 2022511209 A5 JP2022511209 A5 JP 2022511209A5
Authority
JP
Japan
Prior art keywords
group
methyl
pyridine
urea
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020572856A
Other languages
English (en)
Japanese (ja)
Other versions
JP7399122B2 (ja
JP2022511209A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/040595 external-priority patent/WO2020010252A1/en
Publication of JP2022511209A publication Critical patent/JP2022511209A/ja
Publication of JP2022511209A5 publication Critical patent/JP2022511209A5/ja
Application granted granted Critical
Publication of JP7399122B2 publication Critical patent/JP7399122B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020572856A 2018-07-05 2019-07-03 ウレア構造を有する縮合環化合物 Active JP7399122B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862694373P 2018-07-05 2018-07-05
US62/694,373 2018-07-05
PCT/US2019/040595 WO2020010252A1 (en) 2018-07-05 2019-07-03 Fused ring compound having urea structure

Publications (3)

Publication Number Publication Date
JP2022511209A JP2022511209A (ja) 2022-01-31
JP2022511209A5 true JP2022511209A5 (enExample) 2022-07-05
JP7399122B2 JP7399122B2 (ja) 2023-12-15

Family

ID=67480298

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020572856A Active JP7399122B2 (ja) 2018-07-05 2019-07-03 ウレア構造を有する縮合環化合物

Country Status (8)

Country Link
US (2) US11918568B2 (enExample)
EP (1) EP3818053B1 (enExample)
JP (1) JP7399122B2 (enExample)
CN (1) CN112654608B (enExample)
AU (1) AU2019297453B2 (enExample)
CA (1) CA3105456A1 (enExample)
TW (1) TWI812746B (enExample)
WO (1) WO2020010252A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11918568B2 (en) 2018-07-05 2024-03-05 Sanford Burnham Prebys Medical Discovery Institute Fused ring compound having urea structure
EP4103278A1 (en) * 2020-02-12 2022-12-21 Curadev Pharma Pvt. Ltd. Small molecule sting antagonists
WO2021207343A1 (en) * 2020-04-08 2021-10-14 Rheos Medicines, Inc. Malt1 inhibitors and uses thereof
EP4263524A1 (en) 2020-12-21 2023-10-25 Cytokinetics, Inc. Pyrazole derivatives useful as nampt modulators
CN113372276B (zh) * 2021-05-25 2022-04-22 三峡大学 吲唑类衍生物及其应用
GB202110728D0 (en) * 2021-07-26 2021-09-08 Univ Manchester Therapeutic compounds
CN113666862B (zh) * 2021-08-18 2024-05-31 山东大学 一种通过镍催化不对称硝化反应制备手性3-硝基吲哚类化合物的方法
IL319081A (en) * 2022-09-23 2025-04-01 Sironax Ltd NAMPT modulators, their preparations and uses
EP4663628A1 (en) * 2023-02-10 2025-12-17 Samjin Pharmaceutical Co., Ltd. New compound and pharmaceutical composition comprising same
KR20260023474A (ko) * 2024-08-09 2026-02-20 삼진제약주식회사 Nampt 억제제 및 이를 포함하는 항체-약물 접합체

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3128280A (en) 1959-10-23 1964-04-07 Searle & Co 1-(alkoxylated/halogenated phenyl)-3-pyridylmethylureas
US4001256A (en) 1973-12-26 1977-01-04 The Upjohn Company Pyridylalkyl phenyl ureas and their n-oxides
NZ331104A (en) 1995-12-29 2000-03-27 Boehringer Ingelheim Ca Ltd Phenyl thiazole derivatives that inhibit herpes replication by inhibiting the herpes helicase primase enzyme complex
TWI334868B (en) * 2003-06-03 2010-12-21 Nippon Kayaku Kk [1,2,4] triazoro [1,5-a] pyrimidine-2-ylurea derivative and use thereof
US7700592B2 (en) * 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
EP1961745A1 (en) 2005-12-12 2008-08-27 Ono Pharmaceutical Co., Ltd. Bicyclic heterocyclic compound
WO2007086584A1 (ja) 2006-01-30 2007-08-02 Meiji Seika Kaisha, Ltd. 新規FabKおよびFabI/K阻害剤
US20110105457A1 (en) 2008-04-18 2011-05-05 Shionogi & Co., Ltd. Heterocyclic compound having inhibitory activity on pi3k
US20130317027A1 (en) * 2010-03-01 2013-11-28 Myrexis, Inc. Compounds and therapeutic uses thereof
BR112012021806A2 (pt) * 2010-03-01 2015-09-08 Myrexis Inc compostos e seus usos terapêusticos.
AR082886A1 (es) * 2010-09-03 2013-01-16 Forma Therapeutics Inc Compuestos y composiciones farmaceuticas que los contienen
CN106986856A (zh) * 2010-09-03 2017-07-28 福马Tm有限责任公司 作为用于治疗疾病诸如癌症的nampt抑制剂的4‑{[(吡啶‑3‑基‑甲基)氨基羰基]氨基}苯‑砜衍生物
CN102670625B (zh) * 2011-03-18 2014-05-28 中国人民解放军第二军医大学 一种脲类化合物的应用
JP5978293B2 (ja) 2011-05-04 2016-08-24 フォーマ ティーエム, エルエルシー. Namptを阻害するための新規な化合物および組成物
EP2727920B1 (en) * 2011-07-29 2016-11-02 FUJIFILM Corporation 1,5-naphthyridine derivative or salt thereof
WO2013047813A1 (ja) 2011-09-30 2013-04-04 大鵬薬品工業株式会社 1,2,4-トリアジン-6-カルボキサミド誘導体
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2014111871A1 (en) 2013-01-17 2014-07-24 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
EP3004095A1 (de) 2013-06-03 2016-04-13 Bayer Pharma Aktiengesellschaft Triazolopyridine als thrombininhibitoren zur behandlung von thromboembolischen erkrankungen
WO2016198698A2 (en) 2015-06-12 2016-12-15 Cnic Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii P38 inhibitors for the treatment and prophylaxis of liver cancer
US11452717B2 (en) 2017-01-10 2022-09-27 Sanford Burnham Prebys Medical Discovery Institute Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof
US11918568B2 (en) * 2018-07-05 2024-03-05 Sanford Burnham Prebys Medical Discovery Institute Fused ring compound having urea structure

Similar Documents

Publication Publication Date Title
US9024033B2 (en) Anti-malarial agents
CN104066731B (zh) 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类
JP2014513110A5 (enExample)
JP2021534124A5 (enExample)
JP2004504301A5 (enExample)
JP2008508214A (ja) 女性の性障害の治療用ピペラジン誘導体
JP2012515787A5 (enExample)
JP2008513515A5 (enExample)
JP2005508923A5 (enExample)
JP2019521109A5 (enExample)
JP2008524246A5 (enExample)
JP2020516671A5 (enExample)
JP2005536475A5 (enExample)
JP2013531070A5 (enExample)
JP2016519685A5 (enExample)
TW201439090A (zh) 咪唑並吡啶化合物
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
RU2019132212A (ru) Селективные ингибиторы hdac6
JP2014526501A5 (enExample)
JP2017524005A5 (enExample)
JP2009523812A5 (enExample)
JP2011509309A5 (enExample)
JP2021502387A5 (enExample)
JP2006511552A5 (enExample)
JP2018524371A (ja) mIDH1阻害剤としての5−ヒドロキシアルキルベンズイミダゾール